Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.

de Winter-de Groot KM, Janssens HM, van Uum RT, Dekkers JF, Berkers G, Vonk A, Kruisselbrink E, Oppelaar H, Vries R, Clevers H, Houwen RHJ, Escher JC, Elias SG, de Jonge HR, de Rijke YB, Tiddens HAWM, van der Ent CK, Beekman JM.

Eur Respir J. 2018 Sep 17;52(3). pii: 1702529. doi: 10.1183/13993003.02529-2017. Print 2018 Sep.

PMID:
30166324
2.

R560S: A class II CFTR mutation that is not rescued by current modulators.

Awatade NT, Ramalho S, Silva IAL, Felício V, Botelho HM, de Poel E, Vonk A, Beekman JM, Farinha CM, Amaral MD.

J Cyst Fibros. 2018 Jul 18. pii: S1569-1993(18)30643-X. doi: 10.1016/j.jcf.2018.07.001. [Epub ahead of print]

PMID:
30030066
3.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2018 Jun 19. pii: S1569-1993(18)30585-X. doi: 10.1016/j.jcf.2018.05.004. [Epub ahead of print] Review.

4.

Cystic fibrosis: Beyond the airways. Report on the meeting of the basic science working group in Loutraki, Greece.

Amaral MD, Boj SF, Shaw J, Leipziger J, Beekman JM.

J Cyst Fibros. 2018 Jul;17(4):441-443. doi: 10.1016/j.jcf.2018.05.008. Epub 2018 Jun 2. Review.

PMID:
29866530
5.

Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity.

Zomer-van Ommen DD, de Poel E, Kruisselbrink E, Oppelaar H, Vonk AM, Janssens HM, van der Ent CK, Hagemeijer MC, Beekman JM.

J Cyst Fibros. 2018 May;17(3):316-324. doi: 10.1016/j.jcf.2018.02.007. Epub 2018 Mar 13.

PMID:
29544685
6.

Translational research to enable personalized treatment of cystic fibrosis.

Hagemeijer MC, Siegwart DJ, Strug LJ, Cebotaru L, Torres MJ, Sofoluwe A, Beekman JM.

J Cyst Fibros. 2018 Mar;17(2S):S46-S51. doi: 10.1016/j.jcf.2017.10.017. Epub 2017 Dec 21. Review.

PMID:
29275953
7.

Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping.

Vermeulen C, Geeven G, de Wit E, Verstegen MJAM, Jansen RPM, van Kranenburg M, de Bruijn E, Pulit SL, Kruisselbrink E, Shahsavari Z, Omrani D, Zeinali F, Najmabadi H, Katsila T, Vrettou C, Patrinos GP, Traeger-Synodinos J, Splinter E, Beekman JM, Kheradmand Kia S, Te Meerman GJ, Ploos van Amstel HK, de Laat W.

Am J Hum Genet. 2017 Sep 7;101(3):326-339. doi: 10.1016/j.ajhg.2017.07.012. Epub 2017 Aug 24.

8.

Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April, 2016.

Beekman JM, Wang CM, Casati S, Tuggle KL, Gulmans VAM, Amaral M, De Boeck K.

J Cyst Fibros. 2017 Sep;16(5):616-621. doi: 10.1016/j.jcf.2017.04.009. Epub 2017 May 3. No abstract available.

PMID:
28478961
9.

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.

Boj SF, Vonk AM, Statia M, Su J, Vries RR, Beekman JM, Clevers H.

J Vis Exp. 2017 Feb 11;(120). doi: 10.3791/55159.

PMID:
28287550
10.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, Chan M, Conlon S, Davidson HE, Davies JC, Davies LA, Dekkers JF, Doherty A, Gea-Sorli S, Gill DR, Griesenbach U, Hasegawa M, Higgins TE, Hironaka T, Hyndman L, McLachlan G, Inoue M, Hyde SC, Innes JA, Maher TM, Moran C, Meng C, Paul-Smith MC, Pringle IA, Pytel KM, Rodriguez-Martinez A, Schmidt AC, Stevenson BJ, Sumner-Jones SG, Toshner R, Tsugumine S, Wasowicz MW, Zhu J.

Thorax. 2017 Feb;72(2):137-147. doi: 10.1136/thoraxjnl-2016-208406. Epub 2016 Nov 16.

11.

Individualized medicine using intestinal responses to CFTR potentiators and correctors.

Beekman JM.

Pediatr Pulmonol. 2016 Oct;51(S44):S23-S34. doi: 10.1002/ppul.23553. Review.

PMID:
27662101
12.

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.

Noordhoek J, Gulmans V, van der Ent K, Beekman JM.

Curr Opin Pulm Med. 2016 Nov;22(6):610-6. doi: 10.1097/MCP.0000000000000315. Review.

PMID:
27635627
13.

β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.

Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28.

14.

Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.

Zomer-van Ommen DD, Pukin AV, Fu O, Quarles van Ufford LH, Janssens HM, Beekman JM, Pieters RJ.

J Med Chem. 2016 Jul 28;59(14):6968-72. doi: 10.1021/acs.jmedchem.6b00770. Epub 2016 Jul 7.

PMID:
27347611
15.

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.

Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM.

Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278.

PMID:
27334259
16.

Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.

Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Jonge HR, Beekman JM.

J Cyst Fibros. 2016 Sep;15(5):568-78. doi: 10.1016/j.jcf.2016.04.007. Epub 2016 May 5.

17.

Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.

Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Aug;48(2):451-8. doi: 10.1183/13993003.01192-2015. Epub 2016 Apr 21.

18.

rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.

Vidović D, Carlon MS, da Cunha MF, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):288-98. doi: 10.1164/rccm.201505-0914OC.

PMID:
26509335
19.

Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015.

Verkman AS, Edelman A, Amaral M, Mall MA, Beekman JM, Meiners T, Galietta LJ, Bear CE.

J Cyst Fibros. 2015 Nov;14(6):700-5. doi: 10.1016/j.jcf.2015.10.001. Epub 2015 Oct 21. No abstract available.

20.

Modeling rotavirus infection and antiviral therapy using primary intestinal organoids.

Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, Tuysuz N, Dekkers JF, Wang Y, de Jonge J, Sprengers D, van der Laan LJ, Beekman JM, Ten Berge D, Metselaar HJ, de Jonge H, Koopmans MP, Peppelenbosch MP, Pan Q.

Antiviral Res. 2015 Nov;123:120-31. doi: 10.1016/j.antiviral.2015.09.010. Epub 2015 Sep 25.

PMID:
26408355
21.

An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking.

Schneeberger K, Vogel GF, Teunissen H, van Ommen DD, Begthel H, El Bouazzaoui L, van Vugt AH, Beekman JM, Klumperman J, Müller T, Janecke A, Gerner P, Huber LA, Hess MW, Clevers H, van Es JH, Nieuwenhuis EE, Middendorp S.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12408-13. doi: 10.1073/pnas.1516672112. Epub 2015 Sep 21.

22.

Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

Zomer-van Ommen DD, Vijftigschild LA, Kruisselbrink E, Vonk AM, Dekkers JF, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM.

J Cyst Fibros. 2016 Mar;15(2):158-62. doi: 10.1016/j.jcf.2015.07.007. Epub 2015 Aug 5.

23.

A bioassay using intestinal organoids to measure CFTR modulators in human plasma.

Dekkers R, Vijftigschild LA, Vonk AM, Kruisselbrink E, de Winter-de Groot KM, Janssens HM, van der Ent CK, Beekman JM.

J Cyst Fibros. 2015 Mar;14(2):178-81. doi: 10.1016/j.jcf.2014.10.007. Epub 2014 Nov 6.

24.

Modulation of the maladaptive stress response to manage diseases of protein folding.

Roth DM, Hutt DM, Tong J, Bouchecareilh M, Wang N, Seeley T, Dekkers JF, Beekman JM, Garza D, Drew L, Masliah E, Morimoto RI, Balch WE.

PLoS Biol. 2014 Nov 18;12(11):e1001998. doi: 10.1371/journal.pbio.1001998. eCollection 2014 Nov.

25.

CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014.

Beekman JM, Sermet-Gaudelus I, de Boeck K, Gonska T, Derichs N, Mall MA, Mehta A, Martin U, Drumm M, Amaral MD.

J Cyst Fibros. 2014 Jul;13(4):363-72. doi: 10.1016/j.jcf.2014.05.007. Epub 2014 Jun 2. Review. No abstract available.

26.

Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents.

van de Weert-van Leeuwen PB, Hulzebos HJ, Werkman MS, Michel S, Vijftigschild LA, van Meegen MA, van der Ent CK, Beekman JM, Arets HG.

Respir Med. 2014 Mar;108(3):445-52. doi: 10.1016/j.rmed.2013.08.012. Epub 2013 Aug 28.

27.

Effect of long-term voluntary exercise wheel running on susceptibility to bacterial pulmonary infections in a mouse model.

van de Weert-van Leeuwen PB, de Vrankrijker AM, Fentz J, Ciofu O, Wojtaszewski JF, Arets HG, Hulzebos HJ, van der Ent CK, Beekman JM, Johansen HK.

PLoS One. 2013 Dec 23;8(12):e82869. doi: 10.1371/journal.pone.0082869. eCollection 2013.

28.

Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, Beekman JM, Clevers H.

Cell Stem Cell. 2013 Dec 5;13(6):653-8. doi: 10.1016/j.stem.2013.11.002.

29.

A functional CFTR assay using primary cystic fibrosis intestinal organoids.

Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM.

Nat Med. 2013 Jul;19(7):939-45. doi: 10.1038/nm.3201. Epub 2013 Jun 2.

PMID:
23727931
30.

Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, Hegedus T, Beekman JM, Lukacs GL.

Nat Chem Biol. 2013 Jul;9(7):444-54. doi: 10.1038/nchembio.1253. Epub 2013 May 12.

31.

Cell-penetrating bisubstrate-based protein kinase C inhibitors.

van Wandelen LT, van Ameijde J, Ismail-Ali AF, van Ufford HC, Vijftigschild LA, Beekman JM, Martin NI, Ruijtenbeek R, Liskamp RM.

ACS Chem Biol. 2013 Jul 19;8(7):1479-87. doi: 10.1021/cb300709g. Epub 2013 May 8.

PMID:
23621550
32.

Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.

Van de Weert-van Leeuwen PB, Van Meegen MA, Speirs JJ, Pals DJ, Rooijakkers SH, Van der Ent CK, Terheggen-Lagro SW, Arets HG, Beekman JM.

Am J Respir Cell Mol Biol. 2013 Sep;49(3):463-70. doi: 10.1165/rcmb.2012-0502OC.

PMID:
23617438
33.

Infection, inflammation and exercise in cystic fibrosis.

van de Weert-van Leeuwen PB, Arets HG, van der Ent CK, Beekman JM.

Respir Res. 2013 Mar 6;14:32. doi: 10.1186/1465-9921-14-32. Review.

34.

Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis.

van Meegen MA, Terheggen-Lagro SW, Koymans KJ, van der Ent CK, Beekman JM.

PLoS One. 2013;8(3):e57617. doi: 10.1371/journal.pone.0057617. Epub 2013 Mar 6.

35.

Comparison of progestin transcriptional profiles in rat mammary gland using Laser Capture Microdissection and whole tissue-sampling.

Mazurek N, Frisk AL, Beekman JM, Hartwig A, Meyer K.

Exp Toxicol Pathol. 2013 Nov;65(7-8):949-60. doi: 10.1016/j.etp.2013.01.009. Epub 2013 Mar 7.

PMID:
23466250
36.

A novel fluorescent sensor for measurement of CFTR function by flow cytometry.

Vijftigschild LA, van der Ent CK, Beekman JM.

Cytometry A. 2013 Jun;83(6):576-84. doi: 10.1002/cyto.a.22275. Epub 2013 Mar 5.

37.

Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells.

Haveman LM, Bierings M, Klein MR, Beekman JM, de Jager W, Kuis W, Albani S, Prakken BJ.

Clin Immunol. 2013 Mar;146(3):228-39. doi: 10.1016/j.clim.2013.01.002. Epub 2013 Jan 16.

PMID:
23416239
38.

CFTR-mutation specific applications of CFTR-directed monoclonal antibodies.

van Meegen MA, Terheggen SW, Koymans KJ, Vijftigschild LA, Dekkers JF, van der Ent CK, Beekman JM.

J Cyst Fibros. 2013 Sep;12(5):487-96. doi: 10.1016/j.jcf.2012.12.005. Epub 2013 Jan 11.

39.

Novel opportunities for CFTR-targeting drug development using organoids.

Dekkers JF, van der Ent CK, Beekman JM.

Rare Dis. 2013 Nov 11;1:e27112. doi: 10.4161/rdis.27112. eCollection 2013.

40.

A concise preparation of the fluorescent amino acid L-(7-hydroxycoumarin-4-yl) ethylglycine and extension of its utility in solid phase peptide synthesis.

Koopmans T, van Haren M, van Ufford LQ, Beekman JM, Martin NI.

Bioorg Med Chem. 2013 Jan 15;21(2):553-9. doi: 10.1016/j.bmc.2012.10.055. Epub 2012 Nov 21.

PMID:
23238078
41.

Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis.

Speirs JJ, van der Ent CK, Beekman JM.

Curr Opin Pulm Med. 2012 Nov;18(6):632-8. doi: 10.1097/MCP.0b013e328358d50b. Review.

PMID:
22965276
42.

STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass.

de Jong PR, Schadenberg AW, van den Broek T, Beekman JM, van Wijk F, Coffer PJ, Prakken BJ, Jansen NJ.

PLoS One. 2012;7(4):e35070. doi: 10.1371/journal.pone.0035070. Epub 2012 Apr 10.

43.

PPARγ as a therapeutic target in cystic fibrosis.

Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM.

Trends Mol Med. 2012 May;18(5):283-91. doi: 10.1016/j.molmed.2012.03.004. Epub 2012 Apr 9. Review.

PMID:
22494945
44.

CFTR expression analysis in human nasal epithelial cells by flow cytometry.

van Meegen MA, Terheggen-Lagro SW, van der Ent CK, Beekman JM.

PLoS One. 2011;6(12):e27658. doi: 10.1371/journal.pone.0027658. Epub 2011 Dec 7.

45.

Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output.

Beekman JM, Vervoort SJ, Dekkers F, van Vessem ME, Vendelbosch S, Brugulat-Panès A, van Loosdregt J, Braat AK, Coffer PJ.

Oncogene. 2012 May 24;31(21):2668-79. doi: 10.1038/onc.2011.445. Epub 2011 Oct 10.

PMID:
21986941
46.

In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.

Afhüppe W, Beekman JM, Otto C, Korr D, Hoffmann J, Fuhrmann U, Möller C.

J Steroid Biochem Mol Biol. 2010 Mar;119(1-2):45-55. doi: 10.1016/j.jsbmb.2009.12.011. Epub 2010 Jan 4.

PMID:
20043998
47.

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.

van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, Brenkman AB, Hijnen DJ, Mutis T, Kalkhoven E, Prakken BJ, Coffer PJ.

Blood. 2010 Feb 4;115(5):965-74. doi: 10.1182/blood-2009-02-207118. Epub 2009 Dec 7.

48.

Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells.

Vercoulen Y, Wehrens EJ, van Teijlingen NH, de Jager W, Beekman JM, Prakken BJ.

PLoS One. 2009 Sep 25;4(9):e7183. doi: 10.1371/journal.pone.0007183.

49.

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ.

Arthritis Rheum. 2009 Sep;60(9):2782-93. doi: 10.1002/art.24750.

50.

Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output.

Beekman JM, Verhagen LP, Geijsen N, Coffer PJ.

Blood. 2009 Oct 29;114(18):3917-27. doi: 10.1182/blood-2009-03-208850. Epub 2009 Aug 4.

Supplemental Content

Loading ...
Support Center